Tech
We’re still figuring out the side effects of GLP-1 weight-loss drugs
Read it at MIT Technology Review
This week my colleague Antonio Regalado had an interesting update on GLP-1 weight-loss drugs. According to research presented at an aging meeting in Boston, these drugs seem to affect at least some measures of biological age…
- Published
- (2026-10-09)
- Outlet
- MIT Technology Review
- Section
- Tech
- Length here
- Headline and 36-word snippet. The full article is at the source.
More from MIT Technology Review and around the same time
Will the real Anthropic please stand upThis story originally appeared in The Algorithm, our weekly newsletter on AI. To get stories like this in your inbox first, sign up here. After weeks of frenzied speculation, Anthropic has filed its IPO prospectus. The 335-page…The Download: everyday AI harms and the race to nuclear spaceflightThis is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. Opinion: The focus on AI safety disasters ignores everyday harms —Sam Hiner, cofounder of…The focus on AI safety disasters ignores everyday harmsConsider what passes for success in technology policy. An AI company promises that its chatbot will not encourage suicide. A social media platform makes it more difficult for children to buy fentanyl. These are important…The Download: testing six tech promises and biotech’s blind spotsThis is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. Are we there yet? A reality check on six big tech promises Some seemingly impossible feats…In the biotech world, you can’t see everythingEarlier this week, I attended a screening of You Can See Everything, the buzzy new documentary about the disgraced former biotech CEO Elizabeth Holmes. I went in not really knowing what to expect. I’d avoided spoilers (and won’t…Designing an AI serving harness built to lastThe next competitive advantage in enterprise AI has less to do with which model you choose than with what you build around it. That’s an important shift. For the past several years, much of the AI conversation has centered on…This page holds the headline and a short snippet as published by MIT Technology Review, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
